Adriana Alonso Novais

Dr. Adriana Alonso Novais

Universidade Federal de Mato Grosso, Cuiabá, Mato Grosso, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Luiz Gustavo ChuffaLuiz Gustavo Chuffa
Luiz Gustavo Chuffa
FSFabio Seiva
Fabio Seiva
ANAdriana Alonso Novais
Adriana Alonso Novais
Vinícius Augusto SimãoVinícius Augusto Simão
Vinícius Augusto Simão
VGVirna Margarita Martín Giménez
Virna Margarita Martín Giménez
Russel ReiterRussel Reiter
Russel Reiter
The use of nanosized particles has emerged to facilitate selective applications in medicine. Drug-delivery systems represent novel opportunities to provide stricter, focused, and fine-tuned therapy, enhancing the therapeutic efficacy of chemical agents at the molecular level while reducing their toxic effects. Melatonin (N-acetyl-5-methoxytriptamine) is a small indoleamine secreted essentially by the pineal gland during darkness, but also produced by most cells in a non-circadian manner from which it is not released into the blood. Although the therapeutic promise of melatonin is indisputable, aspects regarding optimal dosage, biotransformation and metabolism, route and time of administration, and targeted therapy remain to be examined for proper treatment results. Recently, prolonged release of melatonin has shown greater efficacy and safety when combined with a nanostructured formulation. This review summarizes the role of melatonin incorporated into different nanocarriers (e.g., lipid-based vesicles, polymeric vesicles, non-ionic surfactant-based vesicles, charge carriers in graphene, electro spun nanofibers, silica-based carriers, metallic and non-metallic nanocomposites) as drug delivery system platforms or multilevel determinations in various in vivo and in vitro experimental conditions. Melatonin incorporated into nanosized materials exhibits superior effectiveness in multiple diseases and pathological processes than does free melatonin; thus, such information has functional significance for clinical intervention.

19 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JCJucimara Colombo
Jucimara Colombo
MMMarina Gobbe Moschetta-Pinheiro
Marina Gobbe Moschetta-Pinheiro
ANAdriana Alonso Novais
Adriana Alonso Novais
BSBruna Ribeiro Stoppe
Bruna Ribeiro Stoppe
EBEnrico Dumbra Bonini
Enrico Dumbra Bonini
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari
Introduction: Breast cancer (BC) is the malignant neoplasm with the highest mortality rate in women and female dogs are good models to study BC. Objective: We investigated the efficacy of liquid biopsy to detect gene mutations in the diagnosis and follow-up of women and female dogs with BC. Materials and Methods: In this study, 57 and 37 BC samples were collected from women and female dogs, respectively. After core biopsy and plasma samples were collected, the DNA and ctDNA of the tumor fragments and plasma were processed for next generation sequencing (NGS) assay. After preprocessing of the data, they were submitted to the Genome Analysis ToolKit (GATK). Results: In women, 1788 variants were identified in tumor fragments and 221 variants in plasma; 66 variants were simultaneously detected in tumors and plasma. Conversely, in female dogs, 1430 variants were found in plasma and 695 variants in tumor fragments; 59 variants were simultaneously identified in tumors and plasma. The most frequently mutated genes in the tumor fragments of women were USH2A, ATM, and IGF2R; in female dogs, they were USH2A, BRCA2, and RRM2. Plasma of women showed the most frequent genetic variations in the MAP3K1, BRCA1, and GRB7 genes, whereas plasma from female dogs had variations in the NF1, ERBB2, and KRT17 genes. Mutations in the AKT1, PIK3CA, and BRIP genes were associated with tumor recurrence, with a highly pathogenic variant in PIK3CA being particularly prominent. We also detected a gain-of-function mutation in the GRB7, MAP3K1, and MLH1 genes. Conclusion: Liquid biopsy is useful to identify specific genetic variations at the beginning of BC manifestation and may be accompanied over the entire follow-up period, thereby supporting the clinicians in refining interventions.

30 August 2023 in Animals
Verified
Journal Article
Open access
PDF file
GTGuilherme Henrique Tamarindo
Guilherme Henrique Tamarindo
ANAdriana Alonso Novais
Adriana Alonso Novais
Luiz Gustavo ChuffaLuiz Gustavo Chuffa
Luiz Gustavo Chuffa
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari
Canine mammary tumors (CMTs) are among the most common diseases in female dogs and share similarities with human breast cancer, which makes these animals a model for comparative oncology studies. In these tumors, metabolic reprogramming is known as a hallmark of carcinogenesis whereby cells undergo adjustments to meet the high bioenergetic and biosynthetic demands of rapidly proliferating cells. However, such alterations are also vulnerabilities that may serve as a therapeutic strategy, which has mostly been tested in human clinical trials but is poorly explored in CMTs. In this dedicated review, we compiled the metabolic changes described for CMTs, emphasizing the metabolism of carbohydrates, amino acids, lipids, and mitochondrial functions. We observed key factors associated with the presence and aggressiveness of CMTs, such as an increase in glucose uptake followed by enhanced anaerobic glycolysis via the upregulation of glycolytic enzymes, changes in glutamine catabolism due to the overexpression of glutaminases, increased fatty acid oxidation, and distinct effects depending on lipid saturation, in addition to mitochondrial DNA, which is a hotspot for mutations. Therefore, more attention should be paid to this topic given that targeting metabolic fragilities could improve the outcome of CMTs.

19 October 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
ANAdriana Alonso Novais
Adriana Alonso Novais
GTGuilherme Henrique Tamarindo
Guilherme Henrique Tamarindo
Luiz Gustavo ChuffaLuiz Gustavo Chuffa
Luiz Gustavo Chuffa
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari
Cancer is a complex and heterogeneous disease, influenced by various factors that affect its progression and response to treatment. Although a histopathological diagnosis is crucial for identifying and classifying cancer, it may not accurately predict the disease’s development and evolution in all cases. To address this limitation, liquid biopsy has emerged as a valuable tool, enabling a more precise and non-invasive analysis of cancer. Liquid biopsy can detect tumor DNA fragments, circulating tumor cells, and exosomes released by cancer cells into the bloodstream. Exosomes attracted significant attention in cancer research because of their specific protein composition, which can provide valuable insights into the disease. The protein profile of exosomes often differs from that of normal cells, reflecting the unique molecular characteristics of cancer. Analyzing these proteins can help identify cancer-associated markers that play important roles in tumor progression, invasion, and metastasis. Ongoing research and clinical validation are essential to advance and effectively utilize protein biomarkers in cancer. Nevertheless, their potential to improve diagnosis and treatment is highly promising. This review discusses several exosome proteins of interest in breast cancer, particularly focusing on studies conducted in mammary tissue and cell lines in humans and experimental animals. Unfortunately, studies conducted in canine species are scarce. This emphasis sheds light on the limited research available in this field. In addition, we present a curated selection of studies that explored exosomal proteins as potential biomarkers, aiming to achieve benefits in breast cancer diagnosis, prognosis, monitoring, and treatment.

17 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ANAdriana Alonso Novais
Adriana Alonso Novais
GTGuilherme Henrique Tamarindo
Guilherme Henrique Tamarindo
LMLuryan Mikaelly Minotti Melo
Luryan Mikaelly Minotti Melo
BBBeatriz Castilho Balieiro
Beatriz Castilho Balieiro
DNDaniela Nóbrega
Daniela Nóbrega
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari
(Background). Canine mammary tumors (CMTs) have emerged as an important model for understanding pathophysiological aspects of human disease. Liquid biopsy (LB), which relies on blood-borne biomarkers and offers minimal invasiveness, holds promise for reflecting the disease status of patients. Small extracellular vesicles (SEVs) and their protein cargo have recently gained attention as potential tools for disease screening and monitoring. (Objectives). This study aimed to isolate SEVs from canine patients and analyze their proteomic profile to assess their diagnostic and prognostic potential. (Methods). Plasma samples were collected from female dogs grouped into CMT (malignant and benign), healthy controls, relapse, and remission groups. SEVs were isolated and characterized using ultracentrifugation (UC), nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Proteomic analysis of circulating SEVs was conducted using liquid chromatography–mass spectrometry (LC–MS). (Results). While no significant differences were observed in the concentration and size of exosomes among the studied groups, proteomic profiling revealed important variations. Mass spectrometry identified exclusive proteins that could serve as potential biomarkers for mammary cancer. These included Inter-alpha-trypsin inhibitor heavy chain (ITIH2 and ITI4), phosphopyruvate hydratase or alpha enolase (ENO1), eukaryotic translation elongation factor 2 (eEF2), actin (ACTB), transthyretin (TTR), beta-2-glycoprotein 1 (APOH) and gelsolin (GSN) found in female dogs with malignant tumors. Additionally, vitamin D-binding protein (VDBP), also known as group-specific component (GC), was identified as a protein present during remission. (Conclusions). The results underscore the potential of proteins found in SEVs as valuable biomarkers in CMTs. Despite the lack of differences in vesicle concentration and size between the groups, the analysis of protein content revealed promising markers with potential applications in CMT diagnosis and monitoring. These findings suggest a novel approach in the development of more precise and effective diagnostic tools for this challenging clinical condition.

21 September 2021 in Veterinary and Comparative Oncology
Verified
Journal Article
Closed access
JOJéssica Rodrigues de Oliveira
Jéssica Rodrigues de Oliveira
JCJucimara Colombo
Jucimara Colombo
FGFrancine Moraes Gonçalves
Francine Moraes Gonçalves
Lucas Amoroso Lopes de CarvalhoLucas Amoroso Lopes de Carvalho
Lucas Amoroso Lopes de Carvalho
DCDouglas Santos Costa
Douglas Santos Costa
Debora Aparecida Pires Campos ZuccariDebora Aparecida Pires Campos Zuccari
Debora Aparecida Pires Campos Zuccari